Sumitomo Dainippon Pharma Co. Ltd.

11/26/2021 | Press release | Distributed by Public on 11/25/2021 19:05

Succession of Manufacturing and Marketing Approval and Marketing Rights of REPLAGAL 3.5 mg for Fabry Disease, an α-Galactosidase Enzyme IV Infusion